Tern Plc Konektio £2.5 million equity fundraise

IoT

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that its portfolio company, InVMA Limited, which trades as Konektio has agreed a £2.5 million equity fundraise, to be completed in two tranches. The first tranche of £1.2 million has completed and the second tranche of £1.3 million is due for completion in Q4 2023.

Tern has invested £100,000 in the Konektio First Tranche, with the remainder provided by Konektio’s other institutional shareholders, being Mercia and Foresight.  Prior to the Konektio First Tranche, Tern had a shareholding of 39.9% in Konektio with an unaudited book valuation of £1.0 million.  Post the Konektio First Tranche, Tern’s shareholding in Konektio has reduced to 28% (before any dilution on exercise of any Konektio employee share options) and Tern’s shareholding now has an unaudited book valuation, at the Konektio First Tranche price, of £0.9 million.  

Including its participation in the Konektio First Tranche, Tern has, to date, invested approximately £2.3 million in Konektio.  The pre-new money valuation for the Konektio First Tranche is approximately equivalent to the pre-money valuation for the previous Konektio fundraise announced on 25 April 2023, with Konektio having increased its employee share option pool.

Tern Plc has committed to invest a minimum of £0.28 million in the Konektio Second Tranche, with an option, at its sole discretion, to increase its investment amount up to £0.4 million.  The price of the Konektio Second Tranche will be determined as at 30 September 2023 and will be based on the annualised revenues of Konektio at that time, capped at a pre money valuation of £6.0 million.  Should Tern not fulfil its commitment to invest a minimum of £0.28 million in the Konektio Second Tranche, 75% of Tern’s holding in Konektio will be transferred to a valueless class of Konektio deferred shares.

About Konektio

Konektio provides an Industrial IoT Software as a Service platform to Original Equipment Manufacturers and aftermarket customers, as well as the connected product market. The software enables remote asset monitoring and management to drive productivity improvements. Konektio’s primary product, AssetMinder, is machine agnostic and allows manufacturers to diagnose issues and proactively prescribe services plans, ultimately reducing downtime and improving operational efficiency.  According to the latest filed financial statements for Konektio, for the 12 month period ended 31 December 2021, the business recorded an increase in retained unaudited losses of £0.4 million and at that date had unaudited net assets of approximately £1.8 million.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Fundamental XR builds case for wider surgical simulation adoption

Fundamental XR is expanding the role of virtual simulation in surgical training as hospitals integrate the technology into structured education programmes.

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Search